Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
J Biopharm Stat ; 20(3): 497-507, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-20358432

RESUMO

Moxifloxacin has been the most commonly used positive control in "thorough" QTc (TQT) studies. In a TQT study, the assay sensitivity is often considered to be established if the baseline corrected mean difference in QTc between moxifloxacin and placebo is greater than 5 ms in common practice at one or more prespecified time points and the observed moxifloxacin induced QTc effect over time follows the proper pharmacokinetics profile. To better understand the statistical characteristics of moxifloxacin-induced QTc prolongation and to provide guidance for future studies, 20 TQT studies that involved moxifloxacin have been evaluated. We study the QTc profile of the baseline adjusted mean difference in QTc between moxifloxacin and placebo over time. Zhang (2008) proposed that the moxifloxacin induced QTc effect can be evaluated between 1 and 4 h after a single dose (400 mg) administration near the time (T(max)) of peak concentration instead of all time points (typically 9-12 time points) at which QT was measured for the study drug evaluation. After evaluating 20 TQT studies, we confirm that the maximum moxifloxacin effect occurs in the time window between 1 and 4 h post dose. We also investigate the variability of the data as well as correlations between time points and between regimens. These findings and results can be used as a reference for future studies.


Assuntos
Anti-Infecciosos/efeitos adversos , Arritmias Cardíacas/induzido quimicamente , Compostos Aza/efeitos adversos , Ensaios Clínicos Controlados como Assunto/estatística & dados numéricos , Frequência Cardíaca/efeitos dos fármacos , Modelos Estatísticos , Quinolinas/efeitos adversos , Adolescente , Adulto , Idoso , Anti-Infecciosos/administração & dosagem , Anti-Infecciosos/farmacocinética , Arritmias Cardíacas/diagnóstico , Arritmias Cardíacas/fisiopatologia , Compostos Aza/administração & dosagem , Compostos Aza/farmacocinética , Estudos Cross-Over , Interpretação Estatística de Dados , Eletrocardiografia/estatística & dados numéricos , Feminino , Fluoroquinolonas , Humanos , Masculino , Pessoa de Meia-Idade , Moxifloxacina , Efeito Placebo , Quinolinas/administração & dosagem , Quinolinas/farmacocinética , Valores de Referência , Reprodutibilidade dos Testes , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA